The Indian subcontinent (including India, Pakistan, Bangladesh,Sri Lanka, and Nepal) has among the highest rates of cardiovascular
disease, globally. Currently, the prevalence of coronary artery disease
in the age group of 40-50 years in urban India is 4-fold higher than
in the United States (10% v. 2.5%).
Gennova Biopharmaceuticals, a leading biotechnology company, launches for the first in India, a cutting-edge recombinant fibrin-specific tissue plasminogen activator,
Elaxim TM brand of tenecteplase.
Elaxim TM is a 527 amino acid glycoprotein derived by molecular modification of the native human t-PA, using Chinese Hamster Ovary
Cells, an established mammalian cell line.
Elaxim TM is the only thrombolytic agent that can be administered as a single bolus, in a single injection over 5 seconds. This revolutionary
product thus, offers the fastest administration of a thrombolytic to date
in the treatment of a heart attack, well within the onset of the golden
Since it is easily and quickly delivered and safer because of
lesser bleeding complications, single-bolus Elaxim TM provides an
attractive new standard of care. Elaxim TM was shown to be as effective
as alteplase in terms of mortality at thirty days. This efficiency in
decreasing the rate of mortality is independent of age, location of attack,
or any history of hypertension, diabetes or previous myocardial infarction.